Pipeline & Platform

PT010 is a triple combination product composed of glycopyrrolate, formoterol fumarate and an inhaled corticosteroid (ICS), given twice daily from an HFA-MDI for treatment of severe COPD.

Patients at advanced stages of COPD require all three classes of therapeutic agents for complete management of their disease. PT010 is the first product to deliver the three therapeutic entities via one inhaler, and will couple the dual bronchodilator properties of PT003 with the anti-inflammatory effects of an ICS to achieve maximum bronchodilation with reduction in exacerbations. PT010 will be developed in parallel to PT003, with the evaluation currently focused on selecting an ICS.